New migraine drug is better than placebo at freeing people from pain
Embargoed until:
Publicly released:
2019-11-20 03:00
If you suffer from migraines, a new treatment may be on the horizon as a clinical trial in the US found that the drug ubrogepant can reduce pain associated with migraines. The study of 1686 migraine sufferers showed that around 20 per cent of people were free of pain 2 hours after a 50mg dose of ubrogepant compared to 14 per cent who received a placebo treatment. The study also found more people reported being free from the most bothersome migraine-associated symptoms with a 50-mg dose.
Journal/conference: JAMA
Link to research (DOI): 10.1001/jama.2019.16711
Organisation/s: Albert Einstein College of Medicine, USA
Funder: This trial was sponsored by Allergan plc, Dublin, Ireland. Medical writing and editorial support were provided by Lela Creutz, PhD, and Lisa Feder, PhD, of Peloton Advantage, LLC, an OPEN Health company, Parsippany, New Jersey, and Amy Kuang, PhD, of Allergan plc and funded by Allergan plc.
Media Release
From: JAMA
Treatment of Migraine Pain in Randomized Clinical Trial
What The Study Did: Adults experiencing a migraine of moderate or severe severity took the drug ubrogepant or placebo and reported if after two hours they were free of pain and of their most bothersome migraine-associated symptom in this randomized clinical trial.
Authors: Richard B. Lipton, M.D., of the Albert Einstein College of Medicine in Bronx, New York, is the corresponding author.
Attachments:
Note: Not all attachments are visible to the general public